Thiazolidinediones act primarily by reducing insulin resistance and sulphonylureas act primarily by stimulating release of insulin from functioning pancreatic β -cells.
Tiasolidiindioonid vähendavad insuliiniresistentsust ja sulfonüüluurea derivaadid stimuleerivad insuliini vabanemist funktsioneerivatest pankrease β- rakkudest.